INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.35 USD | -0.89% |
|
-2.79% | -16.63% |
| Apr. 19 | BMO Capital Adjusts Price Target on Incyte to $56 From $64 | MT |
| Apr. 01 | Incyte, China Medical System Sign Collaboration, License Agreement | MT |
Presenter SpeechUnknown Analyst (Analysts)Good morning, everyone. Thanks for joining us, and w...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
52.35
USD
Average target price
75.68
USD
Spread / Average Target
+44.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.63% | 11.86B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -24.88% | 27.69B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B | |
| +1.05% | 7.51B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 08
